CLM-103(YYB-103)

CLM-103(YYB103) is a modified IL13-ligand-based chimeric antigen receptor (CAR) T cell, targeting IL-13 receptor α chain variant 2 (IL13Rα2) for the treatment of GBM.

IL13Rα2 is over-expressed in the majority of GBM tumors (>60%) but not expressed on normal brain tissue and at very limited amount on other normal tissues. So it is an very attractive target for CAR-T cell therapy.

Phase I clinical study is planned in Korea

Mechanism of Action

IL13Rα2 expression is closely associated with that of the mesenchymal GBM subtype and is a prognostic indicator of poor patient survival. This provides the rationale for the development of CAR T cells targeting IL13Rα2.

YYB103, modified IL-13 ligand CAR-T cells, showed strong IL13Rα2-specific effector function with minimal effect on IL13Rα1 expressed normal cells in in vitro test. By this unique design of the tumor targeting domain, we expect that YYB103 have more favorable safety profiles.

YYB103 showed potent anti-cancer activity in mouse orthotopic GBM model by monotherapy or combination with TMZ.

View original